I’ve written before about so-called test-tube burgers and bacon and other lab grown meat. Test-tube burgers Cells like muscle and fat progenitor cells are the basis for these products. Sometimes stem cells may come into play for such “test-tube burgers” as I generally call this type of lab meat. Cost seems to be a main […]
Weekly reads: test-tube burgers, CRISPR for space travel, more tuft cells Read More »
Gene editing continues to advance both in the clinic trial arena and at more basic science levels including a report on a new approach called click editing. The two gene editing papers below highlight the variety of tools now available. Gene Editing papers including click editing Click editing enables programmable genome writing using DNA polymerases
Recommended reads: click editing, CRISPR v. progeria, diapause transcriptional program Read More »
The private cord blood bank industry has promised families all kinds of great things over the years. A typical ad for such cord blood banks might say, “Your child may need cord blood in the future for a cure.” The industry also often uses the analogy of frozen cord blood as an insurance policy for
Combinations of human flesh and robots are more in the news lately. Sometimes the fleshy parts are grown from stem cells in a lab. Robots with fleshy faces Scientists in Japan Give Robots a Fleshy Face and a Smile, NYT. I’m working on a piece about robots in China with small, human brain-like structures. Stay tuned
Recommended reads: flesh-faced robots, ALS, Spina Bifida,neuronal CRISPR Read More »
Can researchers use CAR-T for lupus? It’s always exciting when one’s home institution has an interesting new therapy in development. Here at UC Davis Health, there has been an increasing stream of such encouraging trials in the pipeline. I’ve written before about the promising trial of stem cells for spina bifida. Now there’s news related
Recommended reads: CAR-T for Lupus, CRISPR vision, journal closures Read More »
The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and
Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »
Most of us have heard of organoids but what about the related model called an “assembloid”, which is a term growing in use including from organoid researcher Sergiu Pasca of Stanford? Before we jump into that, be sure to enter The Niche stem cell image contest for your chance to win $100 or some swag.
CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
Where do things stand with the investigative approach of stem cells for diabetes? 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells, Medscape. Not the best headline given the few number of participants here. If your study has only two subjects and one responds, someone is going to say, “50% of people had a
Weekly reads: Vertex stem cells for diabetes update, new CRISPR , immortality Read More »
Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »